|
DE1164829B
(de)
|
1961-04-26 |
1964-03-05 |
Bayer Ag |
Verfahren zur elektrophotographischen Herstellung von Bildern mit Fluessigkeitsaerosolen
|
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4994443A
(en)
|
1982-12-20 |
1991-02-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
US5001116A
(en)
|
1982-12-20 |
1991-03-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
US4551177A
(en)
|
1984-04-23 |
1985-11-05 |
National Starch And Chemical Corporation |
Compressible starches as binders for tablets or capsules
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5391485A
(en)
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
|
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US5974203A
(en)
|
1988-04-11 |
1999-10-26 |
Canon Kabushiki Kaisha |
Pattern recognition communication apparatus for transmitting and receiving image data
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
EP0505552A4
(en)
|
1990-10-12 |
1994-06-08 |
Amgen Inc |
Megakaryocyte maturation factors
|
|
US5387421A
(en)
|
1991-01-31 |
1995-02-07 |
Tsrl, Inc. |
Multi stage drug delivery system
|
|
WO1992014455A1
(en)
|
1991-02-14 |
1992-09-03 |
The Rockefeller University |
METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5358941A
(en)
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
|
US5360352A
(en)
|
1992-12-24 |
1994-11-01 |
The Whitaker Corporation |
Wire retainer for current mode coupler
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US20010056114A1
(en)
|
2000-11-01 |
2001-12-27 |
D'amato Robert |
Methods for the inhibition of angiogenesis with 3-amino thalidomide
|
|
US6114355A
(en)
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US5594637A
(en)
|
1993-05-26 |
1997-01-14 |
Base Ten Systems, Inc. |
System and method for assessing medical risk
|
|
US5698579A
(en)
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
|
US5641758A
(en)
|
1993-11-10 |
1997-06-24 |
Kluge; Michael |
Cytarabine derivatives, the preparation and use thereof
|
|
US6432924B1
(en)
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
|
GB9412394D0
(en)
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
MX9702723A
(es)
|
1994-10-28 |
1998-04-30 |
Advanced Health Med E Systems |
Sistema de administracion de recetas.
|
|
US5593696A
(en)
|
1994-11-21 |
1997-01-14 |
Mcneil-Ppc, Inc. |
Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
|
|
US5619991A
(en)
|
1995-04-26 |
1997-04-15 |
Lucent Technologies Inc. |
Delivery of medical services using electronic data communications
|
|
US5643915A
(en)
|
1995-06-06 |
1997-07-01 |
Andrulis Pharmaceuticals Corp. |
Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
|
|
US5731325A
(en)
|
1995-06-06 |
1998-03-24 |
Andrulis Pharmaceuticals Corp. |
Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
|
|
US5832449A
(en)
|
1995-11-13 |
1998-11-03 |
Cunningham; David W. |
Method and system for dispensing, tracking and managing pharmaceutical trial products
|
|
US6063026A
(en)
|
1995-12-07 |
2000-05-16 |
Carbon Based Corporation |
Medical diagnostic analysis system
|
|
PL195916B1
(pl)
|
1996-07-24 |
2007-11-30 |
Celgene Corp |
Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
AU729247B2
(en)
|
1996-08-12 |
2001-01-25 |
Celgene Corporation |
Novel immunotherapeutic agents and their use in the reduction of cytokine levels
|
|
US5924074A
(en)
|
1996-09-27 |
1999-07-13 |
Azron Incorporated |
Electronic medical records system
|
|
WO1998019649A2
(en)
|
1996-11-05 |
1998-05-14 |
The Children's Medical Center Corporation |
Methods and compositions for inhibition of angiogenesis
|
|
US6131090A
(en)
|
1997-03-04 |
2000-10-10 |
Pitney Bowes Inc. |
Method and system for providing controlled access to information stored on a portable recording medium
|
|
EP0998271B3
(en)
|
1997-06-06 |
2014-10-29 |
Depomed, Inc. |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
AU8909898A
(en)
|
1997-08-22 |
1999-03-16 |
Deka Products Limited Partnership |
Health care system and method for physician order entry
|
|
US5955476A
(en)
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US6096757A
(en)
|
1998-12-21 |
2000-08-01 |
Schering Corporation |
Method for treating proliferative diseases
|
|
JP4695259B2
(ja)
|
1998-03-16 |
2011-06-08 |
セルジーン コーポレイション |
２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
|
|
JPH11286455A
(ja)
|
1998-03-31 |
1999-10-19 |
Kanebo Ltd |
骨髄異形成症候群治療薬
|
|
US6673828B1
(en)
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
US6020358A
(en)
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
US20030013739A1
(en)
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
GB9904585D0
(en)
|
1999-02-26 |
1999-04-21 |
Gemini Research Limited |
Clinical and diagnostic database
|
|
AU771015B2
(en)
|
1999-03-18 |
2004-03-11 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
|
US20010021380A1
(en)
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
US6890547B1
(en)
|
1999-07-16 |
2005-05-10 |
Amato Pharmaceutical Products, Ltd. |
Glycyrrhizin preparations for transmucosal absorption
|
|
US6202923B1
(en)
|
1999-08-23 |
2001-03-20 |
Innovation Associates, Inc. |
Automated pharmacy
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
|
CA2319872C
(en)
|
2000-02-02 |
2012-06-19 |
Chun-Ying Huang |
Pharmaceutical composition for the treatment of hepatocellular carcinoma
|
|
ATE340563T1
(de)
|
2000-02-04 |
2006-10-15 |
Depomed Inc |
DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
|
|
CA2402643A1
(en)
|
2000-03-17 |
2001-09-27 |
Cell Therapeutics, Inc. |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
|
US20020022627A1
(en)
|
2000-03-31 |
2002-02-21 |
Dannenberg Andrew J. |
Inhibition of cyclooxygenase-2activity
|
|
JP4679028B2
(ja)
|
2000-05-15 |
2011-04-27 |
セルジーン コーポレイション |
結腸直腸癌を治療するための組成物および方法
|
|
DE60118571T2
(de)
|
2000-05-15 |
2007-02-01 |
Celgene Corp. |
Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
|
|
AU2001280161A1
(en)
|
2000-08-24 |
2002-03-04 |
Kirin Beer Kabushiki Kaisha |
C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
JP4242651B2
(ja)
|
2000-11-30 |
2009-03-25 |
ザ チルドレンズ メディカル センター コーポレイション |
４−アミノ−サリドマイドエナンチオマーの合成法
|
|
US20020128228A1
(en)
|
2000-12-01 |
2002-09-12 |
Wen-Jen Hwu |
Compositions and methods for the treatment of cancer
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
ES2338534T3
(es)
|
2001-02-27 |
2010-05-10 |
The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services |
Analogos de talidomina como inhibidores de la angiogenesis.
|
|
ES2325916T3
(es)
|
2001-08-06 |
2009-09-24 |
The Children's Medical Center Corporation |
Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
JP4027693B2
(ja)
|
2002-03-20 |
2007-12-26 |
トリニティ工業株式会社 |
塗料送給装置及びバルブユニット
|
|
US20030220254A1
(en)
|
2002-03-29 |
2003-11-27 |
Texas Tech University System |
Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
|
|
JP2005536189A
(ja)
|
2002-04-12 |
2005-12-02 |
セルジーン・コーポレーション |
血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
|
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
CA2752140A1
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
|
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
CA2503150A1
(en)
|
2002-10-31 |
2004-05-21 |
Supergen, Inc. |
Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
|
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US20040152632A1
(en)
|
2002-11-06 |
2004-08-05 |
Wyeth |
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
|
|
US6943249B2
(en)
|
2003-03-17 |
2005-09-13 |
Ash Stevens, Inc. |
Methods for isolating crystalline Form I of 5-azacytidine
|
|
US6887855B2
(en)
|
2003-03-17 |
2005-05-03 |
Pharmion Corporation |
Forms of 5-azacytidine
|
|
CL2004001004A1
(es)
|
2003-05-19 |
2005-03-18 |
Upjohn Co |
Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
KR101164696B1
(ko)
|
2004-04-14 |
2012-07-11 |
셀진 코포레이션 |
골수이형성 증후군의 치료 및 관리를 위한 면역조절화합물의 사용 방법 및 상기 화합물을 포함하는 조성물
|
|
AU2004319759A1
(en)
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20070155791A1
(en)
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
US8058260B2
(en)
|
2006-05-22 |
2011-11-15 |
Xenoport, Inc. |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
|
|
HUE029027T2
(en)
|
2006-08-07 |
2017-01-30 |
Abbvie Biotherapeutics Inc |
Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
|
|
WO2008027049A1
(en)
|
2006-08-30 |
2008-03-06 |
Temple University - Of The Commonwealth System Of Higher Education |
Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
WO2008028193A2
(en)
|
2006-09-01 |
2008-03-06 |
Pharmion Corporation |
Colon-targeted oral formulations of cytidine analogs
|
|
CN102898416A
(zh)
|
2006-09-26 |
2013-01-30 |
细胞基因公司 |
作为抗肿瘤剂的5-取代的喹唑酮衍生物
|
|
KR101593242B1
(ko)
|
2007-09-26 |
2016-02-11 |
셀진 코포레이션 |
６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법
|
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain Compounds, Compositions and Methods
|
|
US20100311683A1
(en)
|
2007-11-01 |
2010-12-09 |
Beach C L |
Cytidine analogs for treatment of myelodysplastic syndromes
|
|
US8846628B2
(en)
|
2008-05-15 |
2014-09-30 |
Celgene Corporation |
Oral formulations of cytidine analogs and methods of use thereof
|
|
PE20140963A1
(es)
|
2008-10-29 |
2014-08-06 |
Celgene Corp |
Compuestos de isoindolina para el tratamiento de cancer
|
|
US8628927B2
(en)
|
2008-11-07 |
2014-01-14 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
|
DK2391355T3
(en)
|
2009-05-19 |
2017-02-27 |
Celgene Corp |
FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION
|
|
SG10201501062SA
(en)
|
2010-02-11 |
2015-04-29 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
CA2829593A1
(en)
|
2011-03-11 |
2012-09-20 |
Celgene Corporation |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
|
|
US20140142128A1
(en)
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
CN107249604A
(zh)
*
|
2014-12-31 |
2017-10-13 |
人类起源公司 |
使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
|
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
|
ES2886657T3
(es)
*
|
2015-06-29 |
2021-12-20 |
Bristol Myers Squibb Co |
Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
|